knowledge -WSS

knowledge

author：knowledge 2025-09-29 21:28:58 - browse：8241

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： 6 solutions to address cancer drug shortages and others

focus

WSS

What don’t we know about an Alzheimer’s drug side effect?

The stability of $0 premiums in Medicare Advantage

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

RSV injection headlines need to be accurate for good uptake

European officials brace for rough respiratory virus season

European officials brace for rough respiratory virus season

knowledge

knowledge

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Cigna, Humana reportedly in talks to merge

Trump demands the U.S. pay no more for drugs than other countries … again

BIO selects John Crowley as new CEO

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Trump demands the U.S. pay no more for drugs than other countries … again

What to do when lifesaving products contribute to climate change

Hollywood unions extend contract negotiations for actors

Lawsuit highlights wrinkle for disputes over surprise medical bills

focus

Some top drug companies are starting to take action on climate

Diagnostic tests are hitting their mathematical limits

Lawsuit highlights wrinkle for disputes over surprise medical bills

Flagship Pioneering launches a new biotech in two countries

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

RSV injection headlines need to be accurate for good uptake

hotspot

focus

Wikipedia

Wikipedia